Welcome to Dermbits! Watch short videos of KOLs answering your questions

thumbnail_dermbits-colorful.png

dermbits-colorful.png

Dermbits

MD, FAAD, FAAP

What were the primary endpoints of the CAMP-1 and CAMP-2 trials?

Warts And Molluscum

You. While the primary efficacy endpoints in both the camp one and camp two trials, we're actually looking at the percentage of patients that received 100% absolute clearance, which is a pretty steep mark in dermatologic research. Oftentimes we're looking for perhaps 75% improvement or 90%, but not 100% in this trial. What we're looking at is the patients that we followed all the way to day 84 and what percentage of those patients actually cleared 100%. And what we saw in the study is that 50% of those treated with the cantherabin achieved absolute clearance by day 84, compared with only 15.6% of the vehicle treated subjects. The secondary efficacy endpoints that were looked at were really the proportion of subjects that actually cleared all of their treated molascom lesions and these patients were followed at day 21, day 42, and ultimately day 63. In the camp one study, the subjects that were treated actually achieved a significantly greater clearance rate than those that were treated by vehicle. And so statistical significant was achieved at day 42 and also day 63 in the camp one trial. Again, we also saw a significant greater clearance than vehicle for subjects by day 21. This was not seen with the camp two trial. Statistical greater improvement was seen with the treated group versus the vehicle control, but statistical significant was achieved at day 42 and 63, but not at day 21. So what does complete clearance means in both the camp one and camp two trials? Complete clearance means that 100% of all of their treated lesions cleared by the certain time point, and so the subjects were followed out to day 84. So, in an exploratory analysis, what was evaluated was the mean percentage of change from baseline to end of study at day 84. And what we saw were that the contherdin treated subjects achieved a 76% reduction in the treated subjects by the end of study with only 0.3% in the vehicle treated group.